On October 2, 2026 Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, reported that it will present the latest preclinical results of its novel costimulatory T cell engager (Cos-TCE) platform in a Rapid Oral Abstract Presentation at the 2026 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting (SITC 2026), taking place from November 4th to 8th, 2026, at the Phoenix Convention Center, Phoenix, Arizona, U.S.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the Poster Presentation
Title: A CD2-based costimulatory T cell engager platform integrating a novel CD3γε/δε-targeting antibody and steric-hindrance-based CD3 masking
Abstract: 15749
Rapid Oral Abstract Presentation
Presenting Author: Dr. Bing Hou, Antengene’s Chief Scientific Officer
Topic Selection: Rapid Oral – Basic 1
Date: Friday, November 6, 2026
Time: 12:30 PM – 01:30 PM (Eastern Time)
01:30 AM – 02:30 AM , November 7 (Beijing Time)
(Press release, Antengene, OCT 2, 2026, View Source [SID1234671249])